| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Taxes paid related to net share settlement upon vesting of restricted stock units | 94 | 51 |
| Net cash provided by financing activities | 425 | -1,063 |
| Net (decrease) increase in cash and cash equivalents and restricted cash | -62,458 | -43,182 |
| Cash and cash equivalents at beginning of period | 97,173 | - |
| Cash and cash equivalents at end of period | 34,715 | - |
Kyverna Therapeutics, Inc. (KYTX)
Kyverna Therapeutics, Inc. (KYTX)